Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DolPHIN-3 postpartum temporary switch to long-acting cabotegravir/rilpivirine in pregnant women with HIV
PACTR202605618548242Phase 4Not yet recruiting
- Sponsor
- University of Cape Town
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Cape Town. Primary endpoint: Antiviral activity and retention in HIV care. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202605618548242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605618548242.